416 related articles for article (PubMed ID: 31188761)
1. The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome.
Chatzis P; Tziomalos K; Pratilas GC; Makris V; Sotiriadis A; Dinas K
Folia Med (Plovdiv); 2018 Dec; 60(4):512-520. PubMed ID: 31188761
[TBL] [Abstract][Full Text] [Related]
2. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological Treatment for Obesity in Adults: An Umbrella Review.
Khalil H; Ellwood L; Lord H; Fernandez R
Ann Pharmacother; 2020 Jul; 54(7):691-705. PubMed ID: 31958967
[No Abstract] [Full Text] [Related]
4. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
[TBL] [Abstract][Full Text] [Related]
5. Diet, physical exercise and Orlistat administration increase serum anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome (PCOS).
Vosnakis C; Georgopoulos NA; Rousso D; Mavromatidis G; Katsikis I; Roupas ND; Mamali I; Panidis D
Gynecol Endocrinol; 2013 Mar; 29(3):242-5. PubMed ID: 23194076
[TBL] [Abstract][Full Text] [Related]
6. Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance.
Song J; Ruan X; Gu M; Wang L; Wang H; Mueck AO
Gynecol Endocrinol; 2018 May; 34(5):413-417. PubMed ID: 29172796
[TBL] [Abstract][Full Text] [Related]
7. The role of orlistat combined with lifestyle changes in the management of overweight and obese patients with polycystic ovary syndrome.
Panidis D; Tziomalos K; Papadakis E; Chatzis P; Kandaraki EA; Tsourdi EA; Katsikis I
Clin Endocrinol (Oxf); 2014 Mar; 80(3):432-8. PubMed ID: 23909452
[TBL] [Abstract][Full Text] [Related]
8. Disparate effects of pharmacotherapy on plasma plasminogen activator inhibitor-1 levels in women with the polycystic ovary syndrome.
Koiou E; Tziomalos K; Katsikis I; Delkos D; Tsourdi EA; Panidis D
Hormones (Athens); 2013; 12(4):559-66. PubMed ID: 24457404
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Tak YJ; Lee SY
Curr Obes Rep; 2021 Mar; 10(1):14-30. PubMed ID: 33410104
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Treatment of Obese Women with Polycystic Ovary Syndrome.
Tzotzas T; Karras SN; Katsiki N
Curr Vasc Pharmacol; 2017; 15(3):218-229. PubMed ID: 28003008
[TBL] [Abstract][Full Text] [Related]
11. Effects of orlistat on serum androgen levels among iranian obese women with polycystic ovarian syndrome.
Salehpour S; Hosseini S; Nazari L; Saharkhiz N; Zademodarres S
JBRA Assist Reprod; 2018 Sep; 22(3):180-184. PubMed ID: 29757582
[TBL] [Abstract][Full Text] [Related]
12. New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists.
Barrea L; Pugliese G; Muscogiuri G; Laudisio D; Colao A; Savastano S
Minerva Endocrinol; 2020 Jun; 45(2):127-137. PubMed ID: 32643356
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic therapy to induce weight loss in women who have obesity/overweight with polycystic ovary syndrome: a systematic review and network meta-analysis.
Wang FF; Wu Y; Zhu YH; Ding T; Batterham RL; Qu F; Hardiman PJ
Obes Rev; 2018 Oct; 19(10):1424-1445. PubMed ID: 30066361
[TBL] [Abstract][Full Text] [Related]
14. Melatonin, Liraglutide, and Naltrexone/Bupropion for the Treatment of Obesity and Medication-Related Weight Gain.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2015 Jun; 53(6):19-22. PubMed ID: 26091546
[TBL] [Abstract][Full Text] [Related]
15. Adipokines, insulin resistance and hyperandrogenemia in obese patients with polycystic ovary syndrome: cross-sectional correlations and the effects of weight loss.
Spanos N; Tziomalos K; Macut D; Koiou E; Kandaraki EA; Delkos D; Tsourdi E; Panidis D
Obes Facts; 2012; 5(4):495-504. PubMed ID: 22854419
[TBL] [Abstract][Full Text] [Related]
16. Overview of new antiobesity drugs.
Hainer V
Expert Opin Pharmacother; 2014 Oct; 15(14):1975-8. PubMed ID: 25100293
[TBL] [Abstract][Full Text] [Related]
17. Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists.
Cena H; Chiovato L; Nappi RE
J Clin Endocrinol Metab; 2020 Aug; 105(8):e2695-709. PubMed ID: 32442310
[TBL] [Abstract][Full Text] [Related]
18. Liraglutide and polycystic ovary syndrome: is it only a matter of body weight?
Pugliese G; de Alteriis G; Muscogiuri G; Barrea L; Verde L; Zumbolo F; Colao A; Savastano S
J Endocrinol Invest; 2023 Sep; 46(9):1761-1774. PubMed ID: 37093453
[TBL] [Abstract][Full Text] [Related]
19. Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: impact on metabolism and fertility.
Panidis D; Tziomalos K; Papadakis E; Vosnakis C; Chatzis P; Katsikis I
Endocrine; 2013 Dec; 44(3):583-90. PubMed ID: 23625194
[TBL] [Abstract][Full Text] [Related]
20. A systematic review of GLP-1 on anthropometrics, metabolic and endocrine parameters in patients with PCOS.
Bader S; Bhatti R; Mussa B; Abusanana S
Womens Health (Lond); 2024; 20():17455057241234530. PubMed ID: 38444070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
